Literature DB >> 7134058

Disseminated intravascular coagulation in newborn infants. Prevalence in autopsies and significance as a cause of death.

M Dairaku, K Sueishi, K Tanaka.   

Abstract

Two hundred and one consecutive autopsies of the newborns were clinicopathologically analyzed for the prevalence of disseminated intravascular coagulation (DIC) and its significance as a cause of death. DIC confirmed histopathologically by the presence of many microthrombi in three or more organs was accompanied in 24 cases (11.9%) with various underlying diseases. Factors predisposing to DIC in the newborns included hyaline membrane disease (29.2%), maternal complications (70.8%) and infections (16.7%). Microthrombi were found in the lungs of all the cases with DIC, but were rare in the kidneys, especially in glomeruli. Visceral lesions of DIC were characterized by a wide diversity of histopathological features including ischemic lesions.

Entities:  

Mesh:

Year:  1982        PMID: 7134058     DOI: 10.1016/S0344-0338(82)80033-2

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation.

Authors:  Akira Shirahata; Jun Mimuro; Hoyu Takahashi; Isao Kitajima; Hajime Tsuji; Yutaka Eguchi; Tadashi Matsushita; Masahiro Kajiki; Goichi Honda; Yoichi Sakata
Journal:  Eur J Pediatr       Date:  2013-09-05       Impact factor: 3.183

Review 2.  Disseminated Intravascular Coagulation in Varying Age Groups Based on Clinical Conditions.

Authors:  Elizabeth Geyer-Roberts; Tanisha Akhand; Alexandra Blanco; Robin Jose; Nayeem Chowdhury; Michael Ea; Eric Gutierrez; Jacqueline Balbuena; Sophia Anagnostis; Claudia Henderson; Alexis Fazio; Alexander Burpee; Robin J Jacobs
Journal:  Cureus       Date:  2022-04-21

3.  A phase 1 trial of nebulised heparin in acute lung injury.

Authors:  Barry Dixon; John D Santamaria; Duncan J Campbell
Journal:  Crit Care       Date:  2008-05-06       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.